CDC’s Worst-Case Coronavirus Model: 214 Million Infected, 1.7 Million Dead (Intelligencer)
A recent CDC projection estimated that the U.S. coronavirus epidemic could infect between 160 million and 214 million people over a period...
‘Amazing potential.’ UM doctor to start stem cell trial for coronavirus patients (Miami Herald)
BY BEN CONARCK APRIL 16, 2020
A team of doctors at the University of Miami won emergency federal approval...
FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome.
Exosomes, Extracellular Vesicles, and the CoronaVirus.
Uploading a Series of Articles on Extracellular Vesicles, Including Potential Effects on the CoronaVirus and ARDS.
Article #1:...
Adding Corbis Pharma (CRBP) $5.55 to Watch List.
Running Clinical Trials Full Steam With $46 Million Banked in Late February.
Not thinly, but lightly traded. Ready,...
Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.
A major Wall Street firm that specializes in Bio and Medtech Companies has a $12 price target out on Athersys from one...
Adding Organicell (BPSR) $0.02 to the Watch List.
Organicell (BBSR). New client, studying now. Thinly, thinly traded and expectedly volatile on an intra-day basis. Like what we’ve read so far...
Athersys (ATHX) Overview and Due Diligence links (Reddit)
I've (Dalek on Reddit) compiled a list of links that might be useful if you are disorganized like myself. If you are...
Immunomedics (IMMU) up 100% Today or $2 Billion in Value & Stand Down VIII:
Bear Comments from Roubini, Jim Chanos, Jim Rogers and James A. Kostohryz
Don't Be That Guy in Denial!
Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Latest article
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.
Can You Imagine Selling Solgenix at $2.00 yesterday.
And to be honest, news wasn't all that big - such...
